ReviewJournal of medical virology2025
Recent Advances in Development of Kaposi's Sarcoma-Associated Herpesvirus-Latency-Associated Nuclear Antigen Targeted Therapies.
Review in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Kaposi's Sarcoma-associated Herpesvirus (KSHV, also named as Human Herpesvirus 8, HHV-8) represents a principal causative agent of several cancers arising in patients with compromised immune systems. The latency-associated nuclear antigen (LANA), encoded by KSHV ORF73, is required for replication, persistence, and gene transcription of the viral KSHV genome. Also, LANA functions contribute to KSHV-induced angiogenesis, oncogenesis, cell proliferation and immune escape. Therefore, LANA represents a promising target for the discovery and development of new anti-KSHV drugs, although no specific treatments directed against KSHV latency are available. In the current review, we summarize recent advances in development of KSHV-LANA targeted therapies and discuss existed challenging as well as potential concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.